This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
by Zacks Equity Research
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
QGEN Stock Might Gain Following New Partnership With ID Solutions
by Zacks Equity Research
QGEN teams up with ID Solutions to boost QIAcuity's reach in oncology dPCR assays, aiming to strengthen its cancer research leadership.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Qiagen (QGEN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN Stock Gains Following the Acquisition of Genoox
by Zacks Equity Research
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
by Zacks Equity Research
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 10% and 4.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
QGEN vs. RGEN: Which Stock Is the Better Value Option?
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bio-Techne Opens New Customer Experience Centre in Germany
by Zacks Equity Research
TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.
HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?
by Moumi Mondal
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?
by Zacks Equity Research
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel
by Zacks Equity Research
QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?
by Moumi Mondal
HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential.
QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
by Zacks Equity Research
QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.